Exogems is an early-stage Swiss biotech company founded to exploit the therapeutic potential of exosomes arising from a revolutionary platform built around the only in-class medical device registered in regenerative medicine by the FDA, namely Lipogems®.
Lipogems® is a sterile single-use medical device intended for the closed-loop processing and transferring of autologous adipose tissue in a single surgical step. Its principle is based on the Mesenchymal Stem Cells (MSC) contained in the fat that are still in their niche and are more efficient and more responsive to environmental stimuli giving very strong regenerative tissues and results upon grafting.
Our mission is to disrupt the field of inflammation and regenerative medicine by enabling consistent production of highly efficacious exosomes by using our unique Lipogems® technology combined with proven, scalable, and cost-effective biopharmaceutical manufacturing know how.
Company Details
- Founded
- -
- Address
- C/o Biopole, Epalinges,1066,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.exogems.com
- Keywords
- exosomes, sepsis, cancer, Adipose tissue, MSC.
- HQ
- Epalinges
Exogems Sa Questions
Exogems Sa's website is http://www.exogems.com
Exogems Sa's LinkedIn profile is https://ch.linkedin.com/company/exogems-sa
Exogems Sa's industry is
Biotechnology Research
Exogems Sa's top competitors are
Cellula Therapeutics Sa,
Pdc Therapeutics,
Rivr,
Volumina Medical,
Oxyprem Ag,
Atreon,
Activen Sa,
Genknowme,
Adaptyv,
Akymed.
Exogems Sa's categories are Biotechnology Research
Exogems Sa's founding year is 2022
